Christina Rossi
CIK: 0001756941
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (25 total)
- Jun 4, 2026CGON
CG Oncology, Inc.
Award(A)DirectDirector Stock Option (right to buy)
9.4K shares- - Nov 24, 2025CGON
CG Oncology, Inc.
Award(A)DirectDirector Stock Option (right to buy)
20.9K shares- - Jul 17, 2025BPMC
Blueprint Medicines Corp
Disposition(D)Direct82.4K shares- - Jul 17, 2025BPMC
Blueprint Medicines Corp
Tender Offer(U)Direct20.6K shares- - Jul 17, 2025BPMC
Blueprint Medicines Corp
Award(A)Direct39.5K shares- - Jul 3, 2025BPMC
Blueprint Medicines Corp
Sale(S)Direct1.2K shares at avg. $128.25$150K - Jun 11, 2025XLO
Xilio Therapeutics, Inc.
Award(A)DirectStock Option (right to buy)
31K shares- - May 19, 2025BPMC
Blueprint Medicines Corp
Sale(S)Direct804 shares at avg. $100.14$81K - May 19, 2025BPMC
Blueprint Medicines Corp
Sale(S)Direct1.4K shares at avg. $100.67$142K - May 19, 2025BPMC
Blueprint Medicines Corp
Sale(S)Direct57 shares at avg. $101.72$6K - May 5, 2025BPMC
Blueprint Medicines Corp
Sale(S)Direct180 shares at avg. $102.82$19K - May 5, 2025BPMC
Blueprint Medicines Corp
Sale(S)Direct607 shares at avg. $100.97$61K - May 5, 2025BPMC
Blueprint Medicines Corp
Sale(S)Direct1.3K shares at avg. $101.77$137K - May 5, 2025BPMC
Blueprint Medicines Corp
Sale(S)Direct144 shares at avg. $103.56$15K - Mar 24, 2025BPMC
Blueprint Medicines Corp
Sale(S)Direct2.3K shares at avg. $95.02$216K - Mar 5, 2025BPMC
Blueprint Medicines Corp
Sale(S)Direct6.5K shares at avg. $88.80$577K - Mar 1, 2025BPMC
Blueprint Medicines Corp
Award(A)Direct13.2K shares- - Feb 20, 2025BPMC
Blueprint Medicines Corp
Sale(S)Direct2.3K shares at avg. $95.14$216K - Jan 21, 2025BPMC
Blueprint Medicines Corp
Sale(S)Direct529 shares at avg. $108.99$58K - Jan 21, 2025BPMC
Blueprint Medicines Corp
Sale(S)Direct816 shares at avg. $110.00$90K - Jan 21, 2025BPMC
Blueprint Medicines Corp
Sale(S)Direct808 shares at avg. $110.78$90K - Jan 21, 2025BPMC
Blueprint Medicines Corp
Sale(S)Direct121 shares at avg. $111.81$14K - Dec 18, 2024BPMC
Blueprint Medicines Corp
Sale(S)Direct2.2K shares at avg. $95.88$208K - Dec 18, 2024BPMC
Blueprint Medicines Corp
Sale(S)Direct108 shares at avg. $96.50$10K - Nov 27, 2024BPMC
Blueprint Medicines Corp
Sale(S)Direct2.3K shares at avg. $95.10$216K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 4, 2026 |  CGON CG Oncology, Inc. | Award(A) Director Stock Option (right to buy) | 9,354 | - | - | Direct |
| Nov 24, 2025 | CGON CG Oncology, Inc. | Award(A) Director Stock Option (right to buy) | 20,889 | - | - | Direct |
| Jul 17, 2025 |  BPMC Blueprint Medicines Corp | Disposition(D) | 82,374 | - | - | Direct |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | Tender Offer(U) | 20,628 | - | - | Direct |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | Award(A) | 39,456 | - | - | Direct |
| Jul 3, 2025 | BPMC Blueprint Medicines Corp | Sale(S) | 1,172 | $128.25 | $150,309 | Direct |
| Jun 11, 2025 |  XLO Xilio Therapeutics, Inc. | Award(A) Stock Option (right to buy) | 31,000 | - | - | Direct |
| May 19, 2025 | BPMC Blueprint Medicines Corp | Sale(S) | 804 | $100.14 | $80,513 | Direct |
| May 19, 2025 | BPMC Blueprint Medicines Corp | Sale(S) | 1,413 | $100.67 | $142,247 | Direct |
| May 19, 2025 | BPMC Blueprint Medicines Corp | Sale(S) | 57 | $101.72 | $5,798 | Direct |
| May 5, 2025 | BPMC Blueprint Medicines Corp | Sale(S) | 180 | $102.82 | $18,508 | Direct |
| May 5, 2025 | BPMC Blueprint Medicines Corp | Sale(S) | 607 | $100.97 | $61,289 | Direct |
| May 5, 2025 | BPMC Blueprint Medicines Corp | Sale(S) | 1,343 | $101.77 | $136,677 | Direct |
| May 5, 2025 | BPMC Blueprint Medicines Corp | Sale(S) | 144 | $103.56 | $14,913 | Direct |
| Mar 24, 2025 | BPMC Blueprint Medicines Corp | Sale(S) | 2,274 | $95.02 | $216,075 | Direct |
| Mar 5, 2025 | BPMC Blueprint Medicines Corp | Sale(S) | 6,495 | $88.80 | $576,756 | Direct |
| Mar 1, 2025 | BPMC Blueprint Medicines Corp | Award(A) | 13,200 | - | - | Direct |
| Feb 20, 2025 | BPMC Blueprint Medicines Corp | Sale(S) | 2,274 | $95.14 | $216,348 | Direct |
| Jan 21, 2025 | BPMC Blueprint Medicines Corp | Sale(S) | 529 | $108.99 | $57,656 | Direct |
| Jan 21, 2025 | BPMC Blueprint Medicines Corp | Sale(S) | 816 | $110.00 | $89,760 | Direct |
| Jan 21, 2025 | BPMC Blueprint Medicines Corp | Sale(S) | 808 | $110.78 | $89,510 | Direct |
| Jan 21, 2025 | BPMC Blueprint Medicines Corp | Sale(S) | 121 | $111.81 | $13,529 | Direct |
| Dec 18, 2024 | BPMC Blueprint Medicines Corp | Sale(S) | 2,166 | $95.88 | $207,676 | Direct |
| Dec 18, 2024 | BPMC Blueprint Medicines Corp | Sale(S) | 108 | $96.50 | $10,422 | Direct |
| Nov 27, 2024 | BPMC Blueprint Medicines Corp | Sale(S) | 2,274 | $95.10 | $216,257 | Direct |
1-25 of 25 transactions
About Rossi Christina
Rossi Christina (SEC CIK 0001756941) files insider reports with the SEC as Director of CG Oncology, Inc. (CGON), CHIEF OPERATING OFFICER of Blueprint Medicines Corp (BPMC) and Director of Xilio Therapeutics, Inc. (XLO).
Signal8 holds 15 ownership filings by Rossi Christina (1 Form 3, 14 Form 4), filed between Dec 2, 2024 and Jun 5, 2026. Those filings report 25 transactions, from Nov 27, 2024 to Jun 4, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Rossi Christina's filings is in DALLAS, TX.
Recent filings by Rossi Christina
- Jun 4, 2026: Grant or award of CGON derivative securities (Form 4, code A).
- Nov 24, 2025: Grant or award of CGON derivative securities (Form 4, code A).
- Jul 17, 2025: Disposition to issuer transaction of BPMC shares (Form 4, code D).
- Jul 17, 2025: Tender of shares transaction of BPMC shares (Form 4, code U).
- Jul 17, 2025: Grant or award of BPMC shares (Form 4, code A).
Other insiders filing for CG Oncology, Inc. (CGON)
- Kalofonos Isabel, Chief Commercial Officer
- POST LEONARD E, Director
- Mulay James, Director
- Liu Brian Guan-Chyun, Director
- Tong Victor Edward Jr, Director
- Graf Susan E, Director